VanEck Pharmaceutical ETF PPH

Medalist Rating as of | See VanEck Investment Hub

Morningstar’s Analysis PPH

Will PPH outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

VanEck Pharmaceutical ETF’s management team is rated Average, but a solid investment process still helps this strategy retain its Morningstar Medalist Rating of Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a sizable cost advantage over competitors, priced within the least expensive fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings PPH

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 63.7
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

13.28 96.6 Mil
Healthcare

Novo Nordisk AS ADR

8.72 63.4 Mil
Healthcare

Johnson & Johnson

6.52 47.4 Mil
Healthcare

AbbVie Inc

6.05 44.0 Mil
Healthcare

Merck & Co Inc

5.16 37.5 Mil
Healthcare

Novartis AG ADR

5.11 37.2 Mil
Healthcare

AstraZeneca PLC ADR

4.83 35.1 Mil
Healthcare

Bristol-Myers Squibb Co

4.77 34.7 Mil
Healthcare

Haleon PLC ADR

4.65 33.8 Mil
Healthcare

Zoetis Inc Class A

4.64 33.8 Mil
Healthcare

Sponsor Center